Drug Type Antibody drug conjugate (ADC) |
Synonyms IMD 2358, IMD2358 |
Action antagonists, agonists, inhibitors |
Mechanism ROR1 antagonists(Inactive tyrosine-protein kinase transmembrane receptor ROR1 antagonists), TLR7 agonists(Toll like receptor 7 agonists), TLR8 agonists(Toll like receptor 8 agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC26H24FN3O6 |
InChIKeyPLXLYXLUCNZSAA-QLXKLKPCSA-N |
CAS Registry1599440-33-1 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Solid tumor | Preclinical | China | 01 May 2025 |